Search Within

Breast Medicine Service

Formats
  1. Journal Article (2206)
  2. Meeting Abstract (1680)
  3. Review (83)
  4. Book Section (69)
  5. Editorial (44)
  6. Conference Paper (28)
  7. Guidelines (27)
  8. Correspondence (16)
  9. Miscellaneous (12)
  10. Research Letter (11)
  11. Book Whole (5)
Groups
  1. Department of Medicine (4181)
  2. Solid Tumor Oncology Division (4181)
  3. Survivorship Research (2373)
  4. GSK Faculty (1516)
  5. Population Sciences Research Program (1369)
  6. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (1144)

More Groups

People
  1. Clifford Hudis (906)
  2. Larry Norton (762)
  3. Mark Robson (684)
  4. Neal Rosen (427)
  5. Andrew Seidman (319)
  6. Kenneth Offit (300)

More People

Years
  1. 2025 (130)
  2. 2024 (195)
  3. 2023 (168)
  4. 2022 (219)
  5. 2021 (236)
  6. 2020 (250)

More Years

Publications
  1. Journal of Clinical Oncology (828)
  2. Cancer Research (481)
  3. Breast Cancer Research and Treatment (170)
  4. Annals of Oncology (159)
  5. Clinical Cancer Research (132)
  6. Cancer (78)

More Publications

Publishers
  1. American Society of Clinical Oncology (880)
  2. American Association for Cancer Research (755)
  3. Springer (332)
  4. Elsevier Inc. (308)
  5. Oxford University Press (282)
  6. Nature Publishing Group (276)

More Publishers

Results (4181)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A randomized placebo controlled study of a plant-based dietary versus supplement versus placebo intervention in patients with monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM) - the Nutrition Prevention (NUTRIVENTION-3) study
    Meeting Abstract

    Shah, U. A.; Castro, F.; Anuraj, A.; Schach, E.; Derkach, A.; Joseph, N. S.; Adintori, P. A.; Guttentag, L.; Blaslov, J.; Cross, J. R.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Brentuximab vedotin combined with chemotherapy in newly diagnosed, early-stage, unfavorable-risk Hodgkin lymphoma: Extended follow-up with evaluation of baseline metabolic tumor volume and PET2
    Meeting Abstract

    Stuver, R.; Michaud, L.; Casulo, C.; Advani, R. H.; Budde, E. L.; Barr, P. M.; Batlevi, C. L.; Caron, P. C.; Constine, L. S.; Dandapani, S.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • RAF-Independent MEK mutations drive histiocytic neoplasms in vivo and are sensitive to single-agent ERK inhibition in patients
    Meeting Abstract

    Durham, B. H.; Singer, M. E.; Benbarche, S.; Erickson, C.; Rahman, J.; Solit, D. B.; Witkowski, M.; Rosen, N.; Abdel-Wahab, O.; Diamond, E. L.
    Blood (2022)

    Fulltext@MSK | Save
  • PIK3CA hotspot mutation generates a shared neoantigen targetable by TCR gene therapy
    Editorial

    Klebanoff, C. A.; Chandran, S. S.
    Nature Medicine (2022)

    Fulltext@MSK | Save
  • Trastuzumab deruxtecan (T-DXd) versus treatment of physician's choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): Results of DESTINY-Breast04, a randomized, phase 3 study
    Meeting Abstract

    Modi, S.; Jacot, W.; Yamashita, T.; Sohn, J.; Vidal, M.; Tokunaga, E.; Tsurutani, J.; Ueno, N. T.; Chae, Y. S.; Lee, K. S.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Primary results from TROPiCS-02: A randomized phase 3 study of sacituzumab govitecan (SG) versus treatment of physician's choice (TPC) in patients (Pts) with hormone receptor-positive/HER2-negative (HR+/HER2-) advanced breast cancer
    Meeting Abstract

    Rugo, H. S.; Bardia, A.; Marine, F.; Cortes, J.; Schmid, P.; Loirat, D.; Tredan, O.; Ciruelos, E.; Dalenc, F.; Pardo, P. G.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Trastuzumab deruxtecan (T-DXd) combinations in patients with HER2-positive advanced or metastatic breast cancer: A phase 1b/2, open-label, multicenter, dose-finding and dose-expansion study (DESTINY-Breast07)
    Meeting Abstract

    Kolberg, H. C.; André, F.; Hamilton, E.; Loi, S.; Schmid, P.; Anders, C.; Yu, T.; Boston, S.; D'cruz, C.; Herbolsheimer, P.; more...
    Oncology Research and Treatment (2022)

    Fulltext@MSK | Save
  • persevERA Breast Cancer (BC): Phase III study evaluating the efficacy and safety of giredestrant (GDC-9545) + palbociclib versus letrozole + palbociclib in patients (pts) with estrogen-receptor-positive, HER2-negative locally advanced or metastatic BC (ER+/HER2– LA/mBC)
    Meeting Abstract

    Müller, V.; Turner, N.; Jhaveri, K.; Bardia, A.; Niikura, N.; Diéras, V.; Barrios, C.; Im, S. A.; Bellet, M.; Chang, C. W.; more...
    Oncology Research and Treatment (2022)

    Fulltext@MSK | Save
  • Multifocal, durable and pathologically-confirmed brain metastasis complete response to trastuzumab deruxtecan
    Meeting Abstract

    Tosi, U.; Moss, N.; Santomasso, B.; Beal, K.; Modi, S.
    Neuro-Oncology (2022)

    Fulltext@MSK | Save
  • Overall survival (OS) results from the phase III TROPiCS-02 study of sacituzumab govitecan (SG) vs treatment of physician's choice (TPC) in patients (pts) with HR+/HER2-metastatic breast cancer (mBC)
    Meeting Abstract

    Rugo, H. S.; Bardia, A.; Marme, F.; Cortes, J.; Schmid, P.; Loirat, D.; Tredan, O.; Ciruelos, E. M.; Dalenc, F.; Pardo, P. G.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save